Urihk Pharmaceuticals
  • Home
  • About Us
    • Our Team
    • The Urihk Partnership
  • Products
    • Antibiotic
    • Antifungal
    • Anticoagulant
    • Immuno modulator
    • Neuro/CNS
  • Services
  • Learn More
    • News
    • Gallery
    • Careers
  • Contact Us
Select Page
Back
Ulinastatin in Moderate to severe & Critically ill patients
Oct 26, 2021

Ulinastatin in Moderate to severe & Critically ill patients

Cytokine Storm in Novel Coronavirus Disease (COVID-19)
Oct 26, 2021

Cytokine Storm in Novel Coronavirus Disease (COVID-19)

Ulinastatin prevents organ dysfunction and reduces mortality in severe acute pancreatitis
Oct 26, 2021

Ulinastatin prevents organ dysfunction and reduces mortality in severe acute pancreatitis

Ulinastatin was found to be effective in managing the patients with sepsis as per recent meta-analysis
Oct 26, 2021

Ulinastatin was found to be effective in managing the patients with sepsis as per recent meta-analysis

Evidence of Ulinastatin in Critical Ill patients of ARDS
Oct 26, 2021

Evidence of Ulinastatin in Critical Ill patients of ARDS

ABOUT URIHK

URIHK pharmaceuticals is a wholly owned subsidiary of UREKA Hong Kong Ltd. We are a vertically integrated pharmaceutical company that launches, registers and distributes innovative products in India.

 

SITEMAP

  • About Us
  • Services
  • Products
  • Careers
  • Privacy Policy

CONTACT US

602-603, Sai Samarth Business Park,
Deonar, Govandi (East),
Mumbai (400088), India

Phone: +91 22 497 01103 / 43286

Email: [email protected]